Publications by authors named "A M Raimbault"
JCO The APHINITY trial (ClinicalTrials.gov identifier: NCT01358877) previously demonstrated that pertuzumab added to adjuvant trastuzumab and chemotherapy improved invasive disease-free survival (iDFS) for patients with early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). Here, we report the preplanned third interim analysis of overall survival (OS) and a descriptive updated iDFS analysis with 8.
View Article and Find Full Text PDFArticle Synopsis
- - Acute myeloid leukemia (AML) with a specific fusion gene is now recognized as a unique subtype, making it crucial to differentiate it from myeloid blast crisis chronic myeloid leukemia (BC-CML), particularly those without a chronic phase.
- - The study analyzed a diverse cohort of CML and AML patients, revealing that the fusion functioned as an essential genetic marker in characterizing AML, while also unearthing AML-specific mutations and distinct gene expression patterns.
- - Findings indicate that specific gene expressions, particularly of mRNAs like ID4, can help differentiate AML with the fusion from BC-CML, suggesting that further research is needed to validate these distinctions and deepen the understanding of this AML subtype.
Article Synopsis
- F-FDG PET/CT is important for diagnosing and monitoring Hairy Cell Leukemia (HCL), especially in atypical cases with bone involvement.
- The study highlighted two patients with BRAF mutation who had significant bone lesions and limited bone marrow infiltration, demonstrating the utility of F-FDG PET/CT.
- The authors emphasize integrating F-FDG PET/CT into standard HCL management to improve patient outcomes and detect less common manifestations.
Article Synopsis
- Patients with Fanconi anemia (FA) show chromosome instability, leading to exhaustion of hematopoietic stem cells and a higher risk of developing poor-prognosis myeloid leukemia.
- A study involving 62 patients revealed unique mutations and structural variants that resemble BRCA-related cancers, with many patients showing chromosome 1q gain linked to MDM4 trisomy, which downregulates p53 signaling.
- MDM4 triplication not only enhances the survival of FA stem cells but also promotes leukemia development, suggesting that targeting MDM4 could be a potential therapeutic strategy to disrupt this pathway.